Ionis Pharmaceuticals (IONS) Misses Q2 EPS by 20c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ionis Pharmaceuticals (IONS) PT Lowered to $47 at Stifel
August 9, 2018 6:24 AM EDTStifel lowered its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $47.00 (from $48.00) while maintaining a Hold rating.
... MoreStifel Transfers Coverage of Ionis Pharmaceuticals (IONS), Maintains Hold
August 6, 2018 4:19 PM EDTStifel assumes coverage on Ionis Pharmaceuticals (NASDAQ: IONS) with a Hold rating and a price target of $48.00.
Analyst Paul Matteis assumes coverage at Hold and lowers the PT to $48.00 (from $55.00)
For an analyst ratings summary and ratings history on Ionis Pharmaceuticals... More
